Clinical

Articles

An analysis of data from a Cleveland Clinic database indicates calcium supplementation in older adults with aortic stenosis was linked to an increased risk of mortality and worsening aortic stenosis. 

Calcium Supplementation and Increased Risk of Death in Older Adults with Cardiovascular Disease

Lauren Biscaldi is the Managing Editor of Drug Topics. 

Class 1C antiarrhythmic drugs were associated with the lowest rate of adverse outcomes. 

Lower Socioeconomic Status Increases Risk of Hospitalization, Death With Antiarrhythmic Drugs

The approval indicates the SGLT2 inhibitor for reducing risk of CV death and hospitalizations for heart failure in adults with heart failure.

Drug Update: FDA Approves Empagliflozin for Adults With Heart Failure

Videos

An expert panel discusses where bempedoic acid currently fits into the treatment of hypercholesterolemia. 

Bempedoic Acid for Hypercholesterolemia

What pharmacists and providers need to know to counsel patients on when discussing the use of prescription or over-the-counter fish oil supplement as treatment for dyslipidemia and hypertriglyceridemia.

Efficacy of Prescription Vs OTC Fish Oil Products 

Takeaways of the REDUCE-IT trial of icosapent ethyl as treatment for dyslipidemia and hypertriglyceridemia.

Implications for Prescribing Icosapent Ethyl to Prevent CVD

An overview of the REDUCE-IT trial of icosapent ethyl for the management of triglycerides and prevention of cardiovascular events.

The REDUCE-IT Trial and CVD Prevention

American Heart Month is a great time for pharmacists to educate the public about their contributions to managing patients with cardiovascular disease.

Become A Champion for Heart Health

The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection fraction.

Empagliflozin Reduces Risk of CV Death, Hospitalization for Heart Failure With Preserved Ejection Fraction

Jennifer Barrett is the senior editor for 

An oral abstract presentation at the American Diabetes Association Virtual 81st Scientific Sessions highlighted a cardioprotective benefit of sodium-glucose co-transporter-2 inhibitors.